This purpose of this study is to determine the ability of an18F-fluoro-L-dihydroxyphenylalanine (18F-DOPA) PET (Positron Emission Tomography) scan todetect a focal lesion of hyperinsulinism and determine the location in patients withcongenital hyperinsulinism, Beckwith Wiedemann Syndrome and suspected insulinoma. Safetydata will be collected.
Patients with hyperinsulinemic hypoglycemia are at risk for neurological damage due to
hypoglycemia. Early surgical intervention can be preventative. F-DOPA PET may be able to
detect of a focal lesion prior to surgical intervention and be used during surgical
planning to guide the surgical procedure.
Drug: 18F-DOPA
18F-DOPA is a PET (Positron Emission Tomography) scan radiotracer.
Other Name: 18F-fluoro-L-dihydroxyphenylalanine,18F-L-Fluoro-DOPA
Inclusion Criteria:
- Subjects of any age with hyperinsulinemic hypoglycemia, diagnosed by a fasting test
and/or response to glucagon stimulation.
- Subjects who are eligible for pancreatic surgery regardless of prior pancreatic
surgery
Exclusion Criteria:
- Pregnant or lactating females
- Any other major illness or condition that in the investigator's judgment will
substantially increase the risk associated with the subject's participation in this
study
- Subjects who are not a candidate for pancreatic surgery
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Investigator: Lisa States, MD
Susan Becker, RN, BSN, CCRC
267-426-0269
Beckers@chop.edu
Lisa States, MD
267-425-7146
States@chop.edu
Lisa States, MD, Principal Investigator
Children's Hospital of Philadelphia